Economic information and modeling report
Budget impact model
1 evidence topic · 10 sources
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
Summary
No budget impact model of AD109 was identified, and AD109 has no published price. The report holds evidence for these inputs of a future model:
- Eligible population: approximately 80 million U.S. people aged 30 to 69 years (prospectus) or 83.7 million U.S. adults aged 20 years and older with an AHI4 of 5 or more (Sönmez et al. 2025); approximately 23 million diagnosed patients active from 2019 to 2024, approximately 3 million new diagnoses per year, and approximately 10.5 million diagnosed but untreated (prospectus, from a National Sleep Foundation survey of 1,015 adults); and, for a PAP-intolerant or refusing population, the SynAIRgy intent-to-treat split of 411 (66.8%) with PAP intolerance and 205 (33.3%) with PAP refusal.
- Comparator and care costs: average costs of $2,105 per year for testing, appointments, treatment devices, and surgery if necessary (Frost & Sullivan 2016); payer costs per subject of $1,840 for a laboratory-based and $1,575 for a home-based diagnostic pathway (Kim et al. 2015); and an incremental lifetime cost of $42,953 for hypoglossal nerve stimulation (Pietzsch et al. 2015). The report quotes no acquisition price for tirzepatide.
- Discontinuation: across the two phase 3 trials combined, overall treatment discontinuation by Week 26 was 35.2% (227) with AD109 and 15.5% (100) with placebo, and treatment discontinuation due to treatment-emergent adverse events by Week 26 was 25.0% (163/653) and 6.7% (43/646); in the LunAIRo main cohort, overall discontinuation at month 12 was 46.5% with AD109 and 25.1% with placebo. For CPAP, termination (cessation of reimbursements) was 23.1%, 37.1%, and 47.7% after 1, 2, and 3 years among 480,000 people (Pépin et al. 2021).